H1N1 Infection - Pipeline Review, H2 2015

Date: September 23, 2015
Pages: 177
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H146044F163EN
Leaflet:

Download PDF Leaflet

H1N1 Infection - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘H1N1 Infection - Pipeline Review, H2 2015’, provides an overview of the H1N1 Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of H1N1 Infection
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for H1N1 Infection and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the H1N1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the H1N1 Infection pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for H1N1 Infection
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
H1N1 Infection Overview
Therapeutics Development
Pipeline Products for H1N1 Infection - Overview
Pipeline Products for H1N1 Infection - Comparative Analysis
H1N1 Infection - Therapeutics under Development by Companies
H1N1 Infection - Therapeutics under Investigation by Universities/Institutes
H1N1 Infection - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
H1N1 Infection - Products under Development by Companies
H1N1 Infection - Products under Investigation by Universities/Institutes
H1N1 Infection - Companies Involved in Therapeutics Development
Adamas Pharmaceuticals, Inc.
Akshaya Bio Inc.
Altimmune, Inc.
Antigen Express, Inc.
Beijing Minhai Biotechnology Co., Ltd
CEL-SCI Corporation
Cilian AG
Crucell N.V.
CSL Limited
EpiVax, Inc.
Etubics Corporation
Gemmus Pharma Inc.
iBio, Inc.
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Kineta, Inc.
Kyowa Hakko Kirin Co., Ltd.
Medicago Inc.
Microbiotix, Inc.
Mucosis B.V.
NanoViricides, Inc.
NewLink Genetics Corporation
Onxeo SA
OPKO Health, Inc.
PDS Biotechnology Corporation
REPLICor Inc.
Sarepta Therapeutics, Inc.
Sirnaomics, Inc.
TaiMed Biologics Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Touchlight Genetics Limited
United Therapeutics Corporation
Vaxart, Inc.
Visterra, Inc.
H1N1 Infection - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADS-324 - Drug Profile
AEA-35p - Drug Profile
Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza - Drug Profile
Aspidasept - Drug Profile
BA-032 - Drug Profile
C-05 - Drug Profile
CiFlu - Drug Profile
CR-9114 - Drug Profile
CYM-5442 - Drug Profile
diridavumab - Drug Profile
EP-67 - Drug Profile
Fludase - Drug Profile
FVH-1 - Drug Profile
Gamma-Flu - Drug Profile
GP-1001 - Drug Profile
GP-1681 - Drug Profile
GREFLU/CAL - Drug Profile
H1N1 [A/Aichi/2/68] vaccine - Drug Profile
Human Antibody Based Vaccines - Drug Profile
Influ-nRNA - Drug Profile
influenza (strain H5N1, H1N1) vaccine - Drug Profile
influenza [A/California/04/09 (H1N1)] vaccine - Drug Profile
influenza [H1N1] vaccine - Drug Profile
influenza [strain A/H1N1] vaccine - Drug Profile
influenza [strain H1N1] (monovalent) vaccine - Drug Profile
influenza [strain H1N1] (mutivalent) vaccine - Drug Profile
influenza [strain H1N1] vaccine - Drug Profile
influenza [strain H1N1] vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
influenza [Strains H1N1, H3N2, influenza B] (quadrivalent) virus like particle vaccine - Drug Profile
influenza A vaccine - Drug Profile
influenza vaccine - Drug Profile
influenza vaccine - Drug Profile
influenza vaccine - Drug Profile
LEAPS-H1N1-DC - Drug Profile
MBX-2329 - Drug Profile
MBX-2546 - Drug Profile
Monoclonal Antibody for Influenza A Infections - Drug Profile
NVINF-1 - Drug Profile
NVINF-2 - Drug Profile
PDS-0102 - Drug Profile
pertussis [strain BPZE1] vaccine - Drug Profile
PNSIA-28 - Drug Profile
PNSIA-49 - Drug Profile
radavirsen - Drug Profile
REP-9 - Drug Profile
RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile
seasonal influenza vaccine - Drug Profile
Small Molecule to Agonize IRF-3 for Viral Infections - Drug Profile
Small Molecules for RSV and Influenza A Infections - Drug Profile
Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile
STP-702 - Drug Profile
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
TMB-571 - Drug Profile
TVX-002 - Drug Profile
Vaccine to Target TLR2 for Infectious Disease - Drug Profile
VH-244 - Drug Profile
VIS-410 - Drug Profile
VXAA-1.1 - Drug Profile
Z-3G1 - Drug Profile
H1N1 Infection - Recent Pipeline Updates
H1N1 Infection - Dormant Projects
H1N1 Infection - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for H1N1 Infection, H2 2015
Number of Products under Development for H1N1 Infection - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
H1N1 Infection - Pipeline by Adamas Pharmaceuticals, Inc., H2 2015
H1N1 Infection - Pipeline by Akshaya Bio Inc., H2 2015
H1N1 Infection - Pipeline by Altimmune, Inc., H2 2015
H1N1 Infection - Pipeline by Antigen Express, Inc., H2 2015
H1N1 Infection - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
H1N1 Infection - Pipeline by CEL-SCI Corporation, H2 2015
H1N1 Infection - Pipeline by Cilian AG, H2 2015
H1N1 Infection - Pipeline by Crucell N.V., H2 2015
H1N1 Infection - Pipeline by CSL Limited, H2 2015
H1N1 Infection - Pipeline by EpiVax, Inc., H2 2015
H1N1 Infection - Pipeline by Etubics Corporation, H2 2015
H1N1 Infection - Pipeline by Gemmus Pharma Inc., H2 2015
H1N1 Infection - Pipeline by iBio, Inc., H2 2015
H1N1 Infection - Pipeline by ILiAD Biotechnologies, LLC, H2 2015
H1N1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
H1N1 Infection - Pipeline by Kineta, Inc., H2 2015
H1N1 Infection - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
H1N1 Infection - Pipeline by Medicago Inc., H2 2015
H1N1 Infection - Pipeline by Microbiotix, Inc., H2 2015
H1N1 Infection - Pipeline by Mucosis B.V., H2 2015
H1N1 Infection - Pipeline by NanoViricides, Inc., H2 2015
H1N1 Infection - Pipeline by NewLink Genetics Corporation, H2 2015
H1N1 Infection - Pipeline by Onxeo SA, H2 2015
H1N1 Infection - Pipeline by OPKO Health, Inc., H2 2015
H1N1 Infection - Pipeline by PDS Biotechnology Corporation, H2 2015
H1N1 Infection - Pipeline by REPLICor Inc., H2 2015
H1N1 Infection - Pipeline by Sarepta Therapeutics, Inc., H2 2015
H1N1 Infection - Pipeline by Sirnaomics, Inc., H2 2015
H1N1 Infection - Pipeline by TaiMed Biologics Inc., H2 2015
H1N1 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
H1N1 Infection - Pipeline by TechnoVax, Inc., H2 2015
H1N1 Infection - Pipeline by Touchlight Genetics Limited, H2 2015
H1N1 Infection - Pipeline by United Therapeutics Corporation, H2 2015
H1N1 Infection - Pipeline by Vaxart, Inc., H2 2015
H1N1 Infection - Pipeline by Visterra, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
H1N1 Infection Therapeutics - Recent Pipeline Updates, H2 2015
H1N1 Infection - Dormant Projects, H2 2015
H1N1 Infection - Dormant Projects (Contd..1), H2 2015
H1N1 Infection - Dormant Projects (Contd..2), H2 2015
H1N1 Infection - Dormant Projects (Contd..3), H2 2015

LIST OF FIGURES

Number of Products under Development for H1N1 Infection, H2 2015
Number of Products under Development for H1N1 Infection - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Adamas Pharmaceuticals, Inc.
Akshaya Bio Inc.
Altimmune, Inc.
Antigen Express, Inc.
Beijing Minhai Biotechnology Co., Ltd
CEL-SCI Corporation
Cilian AG
Crucell N.V.
CSL Limited
EpiVax, Inc.
Etubics Corporation
Gemmus Pharma Inc.
iBio, Inc.
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Kineta, Inc.
Kyowa Hakko Kirin Co., Ltd.
Medicago Inc.
Microbiotix, Inc.
Mucosis B.V.
NanoViricides, Inc.
NewLink Genetics Corporation
Onxeo SA
OPKO Health, Inc.
PDS Biotechnology Corporation
REPLICor Inc.
Sarepta Therapeutics, Inc.
Sirnaomics, Inc.
TaiMed Biologics Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Touchlight Genetics Limited
United Therapeutics Corporation
Vaxart, Inc.
Visterra, Inc.
Skip to top


Influenza A Infections - Pipeline Review, H2 2014 US$ 1,500.00 Sep, 2014 · 141 pages

Ask Your Question

H1N1 Infection - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: